Trailing-twelve-month (TTM) revenue is $4.24 Billion with a year-over-year growth of +4.73%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2025Period ended 2025-10-31 | $1,065,200,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-05 |
| Q1 FY2026Period ended 2026-01-31 | $1,024,099,999 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-06 |
| Q2 FY2026Period ended 2026-04-30 | $1,081,500,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-05 |
| Q3 FY2026Period ended 2026-07-31 | $1,066,200,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-09-09 |
| TTM revenue | $4,236,999,999 |
Current P/S: $10,514,121,210 market capitalization ÷ $4,236,999,999 TTM revenue = 2.48x.
Market capitalization source: FMP quote. Quote observed 2026-09-11T20:00:01.000Z. Latest revenue period ended 2026-07-31.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q3 FY2026 (2026-07-31): $1.07B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-12T00:15:25.511Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-10.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-10-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-10-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-10-31 · USD | FY20212021-10-31 · USD | FY20222022-10-31 · USD | FY20232023-10-31 · USD | FY20242024-10-31 · USD | FY20252025-10-31 · USD |
|---|---|---|---|---|---|---|
| Coopersurgical Segment | $588M | $771M | $1.1B | $1.2B | $1.3B | $1.3B |
| Coopervision Segment | $1.8B | $2.2B | $2.2B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-10-31 · USD | FY20212021-10-31 · USD | FY20222022-10-31 · USD | FY20232023-10-31 · USD | FY20242024-10-31 · USD | FY20252025-10-31 · USD |
|---|---|---|---|---|---|---|
| Europe | $1.1B | $1.8B | $1.9B | $2.1B | $2.2B | $2.4B |
| Rest Of World, Excluding United States And Europe | $538M | $625M | $683M |
$4.24B
$4.24 Billion
+4.73%
vs. $4.05B a year ago (TTM)
+8.29%
5 Year compound annual growth rate
1 Year
+4.73%
3 Year
+6.43%
5 Year
+8.29%
10 Year
+8.33%
15 Year
+8.29%
20 Year
+8.28%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $4.09B | +$197.00M | +5.06% |
| 2024 | $3.90B | +$302.20M | +8.41% |
| 2023 | $3.59B | +$284.80M | +8.61% |
| 2022 | $3.31B | +$385.90M | +13.20% |
| 2021 | $2.92B | +$491.60M | +20.22% |
| 2020 |
TTM Growth
+4.73%
3-Year CAGR
+6.43%
5-Year CAGR
+8.29%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-12T00:15:25.511Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-10.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $2.6B |
| $2.7B |
| $774M |
| $785M |
| UNITED STATES | $1.5B | $1.8B | $2.2B | $2.4B | $2.6B | $2.7B |
|---|
| $2.43B |
| ($222.50M) |
| (8.39%) |
| 2019 | $2.65B | +$120.60M | +4.76% |
| 2018 | $2.53B | +$393.80M | +18.41% |
| 2017 | $2.14B | +$172.19M | +8.75% |
| 2016 | $1.97B | +$169.75M | +9.45% |
